Michael Ehlers
General Partner at ATP
Boston, Massachusetts
Overview
Work Experience
Entrepreneur Partner
2024 - Current
Advance the science-driven investment strategy at a leading life sciences fund by identifying and evaluating new breakthrough science around the world and turning it into business plans, management teams, and drug discovery and development programs.
MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
Board Member
2025
Scientific and corporate leadership of pre-clinical stage biotechnology company developing novel RNA therapies for the treatment of cancer, autoimmune disease, infectious disease, and hematologic disease.
Orna Therapeutics is a biotechnology company that specializes in fully engineered circular RNA therapeutics to treat various diseases.
Raised $321,000,000.00 from MPM Capital, BioImpact and Merck.
Board Member
2025
Scientific and corporate leadership of clinical stage biotechnology company developing novel psychedelic therapies for the treatment of psychiatric disease.
Founder, President, and Chief Executive Officer
2023
Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.
Founder and Board Chair
2022 - 2023
Scientific and corporate leadership of research stage biotechnology company developing designer synthetic RNA therapeutics and RNA exon editing therapies for ophthalmological, neurological, neuromuscular, and rare diseases.
Founder, President and Chief Executive Officer
2020 - 2022
Lead all activities at a research stage biotechnology company focused on designer synthetic RNA therapeutics and RNA exon editing. Deploying innovative technology platforms to create breakthrough therapies for debilitating ophthalmological, neurological, neuromuscular, and rare diseases.
Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.
Raised $90,000,000.00 from Apple Tree Partners and Apple Tree Partners.
Co-Founder and Board Member
2021
Scientific and corporate leadership of research stage biotechnology company developing novel self-replicating RNA therapies for cancer, autoimmune disorders, and infectious diseases.
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform.
Raised $46,000,000.00 from Apple Tree Partners.
Co-Founder and Board Member
2020
Scientific and corporate leadership of research stage biotechnology company developing novel immunotherapies for the treatment of diverse cancers.
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Raised $60,000,000.00 from Apple Tree Partners and Apple Tree Partners.
Chief Scientific Officer, General Partner
2024 - 2024
Chief Scientific Officer, Venture Partner
2019 - 2024
Apple Tree Partner's (ATP’s) unique model follows the science, brings together the best teams, and deploys significant capital to create and build the next generation of innovative biotechnology companies.
Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Raised $5,000,000.00.
Founder and Board Chair
2023 - 2023
Scientific and corporate leadership of research stage biotechnology company developing non-viral gene therapies for ophthalmological diseases.
Founder, President, and Chief Executive Officer
2020 - 2023
Led all activities at a cutting-edge start-up biotechnology company focused on non-viral gene therapy. Deploying molecular biology and bioengineering platforms to create breakthrough therapies in ophthalmology.
Intergalactic Therapeutics is an ATP company, is revolutionizing gene therapies with a novel non-viral platform.
Raised $75,000,000.00 from Apple Tree Partners.
Chief Executive Officer
2019 - 2020
Led a cutting-edge start-up biotech company focused on gene therapy and genetic medicines for patients with severe inherited diseases.
Executive Vice President
2016 - 2019
led global R&D for a cutting edge, industry-leading biotechnology company
Biogen is a biotechnology company engaged in the development of innovative therapies for neurological and neurodegenerative diseases.